Ke Li

EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression

Shunli Peng, Rong Wang, Xiaojuan Zhang et al. · Molecular Cancer · 2019 · 320 citations · Full text

Medicine, Oncology, Pharmacology +17

Untargeted metabolomics identifies succinate as a biomarker and therapeutic target in aortic aneurysm and dissection

Hongtu Cui, Yanghui Chen, Ke Li et al. · European Heart Journal · 2021 · 160 citations · Full text

Life Sciences, Biochemistry, Cardiology +17

A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors

Junning Cao, Jian Zhang, Wei Peng et al. · Cancer Chemotherapy and Pharmacology · 2016 · 72 citations

Medicine, Pharmacokinetics, Pharmacology +16

Immuno-PET imaging of 68Ga-labeled nanobody Nb109 for dynamic monitoring the PD-L1 expression in cancers

Qingzhu Liu, Lei Jiang, Ke Li et al. · Cancer Immunology Immunotherapy · 2021 · 69 citations · Full text

Medicine, Nuclear Medicine, Oncology +16

A biotin receptor-targeted silicon(IV) phthalocyanine for in vivo tumor imaging and photodynamic therapy

Ke Li, Wenyi Dong, Qingzhu Liu et al. · Journal of Photochemistry and Photobiology B Biology · 2018 · 66 citations

Medicine, Biomedical Engineering, Oncology +16